New dosage formulations for targeted delivery of cyclo-oxygenase-2 inhibitors - Focus on use in the elderly

被引:19
作者
Bansal, Shyam S. [1 ]
Joshi, Abhijeet
Bansal, Arvind K.
机构
[1] Natl Inst Pharmaceut Educ & Res, Dept Pharmaceut, SAS Nagar, Punjab, India
[2] Natl Inst Pharmaceut Educ & Res, Dept Pharmaceut Technol, SAS Nagar, Punjab, India
关键词
NONSTEROIDAL ANTIINFLAMMATORY DRUGS; DIABETIC-RETINOPATHY; LUNG-CANCER; IN-VITRO; CYCLOOXYGENASE INHIBITORS; PENETRATION ENHANCERS; INTRAOCULAR DELIVERY; SUSTAINED-RELEASE; COX-2; INHIBITORS; NIMESULIDE GEL;
D O I
10.2165/00002512-200724060-00001
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
NSAIDs are a widely used class of analgesic and anti-inflammatory drugs that act by inhibiting the cyclo-oxygenase (COX) enzyme. However, because of their nonspecificity of action, use of these agents as long-term therapy for chronic pain in diseases such as rheumatoid arthritis (RA) and osteoarthritis (OA) is often discouraged. Among NSAIDs, COX-2 inhibitors are promising candidates for long-term therapy of chronic diseases, particularly in the elderly, because of their reduced incidence of gastrointestinal adverse effects. However, in recent times these agents have also been shown to cause adverse effects such as cardiovascular effects (myocardial infarction, stroke and hypertension) and renal effects (decreased renal blood flow/glomerular filtration rate), which in 2004 led to the withdrawal of rofecoxib and in 2005 the withdrawal of valdecoxib from the US market. Importantly, these adverse effects can be effectively reduced by achieving site specific/targeted delivery through new formulation approaches. These formulations not only restrict the drug supply to specific organs but also reduce the dose required. As a result, use of now delivery systems such as nanoparticles, microparticles, microemulsions and nanogels has gained widespread applicability in the management of chronic disease, especially in the elderly, and particularly when there is a need to decrease dose-dependent adverse effects (as is the case with COX-2 inhibitors). This article reviews various new approaches to the delivery of COX-2 inhibitors and highlights issues related to the development of delivery systems for these agents for RA, OA, cancer (familial adenomatous polyposis, prostate, breast and non-small cell lung cancer), ocular diseases (such as diabetic retinopathy) and inflammatory diseases of the skin, with emphasis on their potential for use in the elderly. Emphasis is also placed on the preparation of these particulate systems, their release profile and behaviour in biological systems.
引用
收藏
页码:441 / 451
页数:11
相关论文
共 85 条
[1]   Diabetic retinopathy [J].
Aiello, LP ;
Gardner, TW ;
King, GL ;
Blankenship, G ;
Cavallerano, JD ;
Ferris, FL ;
Klein, R .
DIABETES CARE, 1998, 21 (01) :143-156
[2]  
Alves PM, 2005, PHARMAZIE, V60, P900
[3]   Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2,VEGF, and vascular leakage [J].
Amrite, AC ;
Ayalasomayajula, SP ;
Cberuvu, NPS ;
Kompella, UB .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2006, 47 (03) :1149-1160
[4]   Size-dependent disposition of nanoparticles and microparticles following subconjunctival administration [J].
Amrite, AC ;
Kompella, UB .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2005, 57 (12) :1555-1563
[5]  
ASSIL KK, 1988, OPHTHALMIC SURG LAS, V19, P408
[6]   Subconjunctivally administered celecoxib-PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxidative stress in a rat model [J].
Ayalasomayajula, SP ;
Kompella, UB .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2005, 511 (2-3) :191-198
[7]   Retinal delivery of celecoxib is several-fold higher following subconjunctival administration compared to systemic administration [J].
Ayalasomayajula, SP ;
Kompella, UB .
PHARMACEUTICAL RESEARCH, 2004, 21 (10) :1797-1804
[8]   Inhibition of cyclooxygenase-2, but not cyclooxygenase-1, reduces prostaglandin E2 secretion from diabetic rat retinas [J].
Ayalasomayajula, SP ;
Amrite, AC ;
Kompella, UB .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2004, 498 (1-3) :275-278
[9]   DRUG-THERAPY - INHALED GLUCOCORTICOIDS FOR ASTHMA [J].
BARNES, PJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (13) :868-875
[10]  
Barouch FC, 2000, INVEST OPHTH VIS SCI, V41, P1153